Search results
Results from the WOW.Com Content Network
Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [1] [2] [3] It combines efavirenz, lamivudine, and tenofovir disoproxil. [3]
These changes minimize interactions between drugs, lower clearance, and increase solubility. Bictegravir was found to be less drug resistant than other drugs in the same class. [16] Emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor (NRTI) that is a synthetic fluoro derivative of thiacytidine. Within the cell, emtricitabine ...
Both medications are HIV protease inhibitors. [4] Ritonavir functions by slowing down the breakdown of lopinavir. [4] Lopinavir/ritonavir as a combination medication was approved for use in the United States in 2000. [4] It is on the World Health Organization's List of Essential Medicines. [5]
For premium support please call: 800-290-4726 more ways to reach us
Lamivudine is a nucleoside reverse transcriptase inhibitor and works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase. [1] Lamivudine was patented in 1995 and approved for use in the United States in 1995. [8] [9] It is on the World Health Organization's List of Essential Medicines. [10] It is available as a generic ...
In 2012, the FDA approved the drug for use as pre-exposure prophylaxis (PrEP), based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection. [41] The FDA has approved two additional medications for PrEP since then, approving Descovy in 2019 and Cabotegravir (Apretude) in 2021. [4 ...